CN113855729A - 一种用于防治鸡禽流感的复方黄芪多糖颗粒 - Google Patents
一种用于防治鸡禽流感的复方黄芪多糖颗粒 Download PDFInfo
- Publication number
- CN113855729A CN113855729A CN202111275085.0A CN202111275085A CN113855729A CN 113855729 A CN113855729 A CN 113855729A CN 202111275085 A CN202111275085 A CN 202111275085A CN 113855729 A CN113855729 A CN 113855729A
- Authority
- CN
- China
- Prior art keywords
- parts
- mixture
- weight
- astragalus
- honeysuckle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000006533 astragalus Nutrition 0.000 title claims abstract description 79
- 241001061264 Astragalus Species 0.000 title claims abstract description 71
- 210000004233 talus Anatomy 0.000 title claims abstract description 71
- 150000004676 glycans Chemical class 0.000 title claims abstract description 67
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 67
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 67
- 150000001875 compounds Chemical class 0.000 title claims abstract description 49
- 206010064097 avian influenza Diseases 0.000 title claims abstract description 43
- 208000002979 Influenza in Birds Diseases 0.000 title claims abstract description 40
- 239000008187 granular material Substances 0.000 title claims abstract description 18
- 241000287828 Gallus gallus Species 0.000 title claims description 26
- 235000013330 chicken meat Nutrition 0.000 title claims description 26
- 239000002245 particle Substances 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 21
- 210000000582 semen Anatomy 0.000 claims abstract description 20
- 241000218206 Ranunculus Species 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 10
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 9
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 229920001353 Dextrin Polymers 0.000 claims abstract description 3
- 239000004375 Dextrin Substances 0.000 claims abstract description 3
- 229920002472 Starch Polymers 0.000 claims abstract description 3
- 235000019425 dextrin Nutrition 0.000 claims abstract description 3
- 235000019698 starch Nutrition 0.000 claims abstract description 3
- 239000008107 starch Substances 0.000 claims abstract description 3
- 240000000031 Achyranthes bidentata Species 0.000 claims description 15
- 241000334160 Isatis Species 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 14
- 238000002386 leaching Methods 0.000 claims description 14
- 241000125175 Angelica Species 0.000 claims description 12
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000003825 pressing Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 238000004537 pulping Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 241000555682 Forsythia x intermedia Species 0.000 claims 1
- 229940100688 oral solution Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 244000144977 poultry Species 0.000 abstract description 24
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 239000010231 banlangen Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 34
- 235000013594 poultry meat Nutrition 0.000 description 23
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 238000011160 research Methods 0.000 description 15
- 230000036039 immunity Effects 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 230000002708 enhancing effect Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 241000427159 Achyranthes Species 0.000 description 7
- 229960001280 amantadine hydrochloride Drugs 0.000 description 7
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 244000144972 livestock Species 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 230000036737 immune function Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000555712 Forsythia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 244000144992 flock Species 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 208000035240 Disease Resistance Diseases 0.000 description 4
- 201000000297 Erysipelas Diseases 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 235000009815 Momordica Nutrition 0.000 description 4
- 241000218984 Momordica Species 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 230000024121 nodulation Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000017448 oviposition Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000224483 Coccidia Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 241000334154 Isatis tinctoria Species 0.000 description 2
- 240000001910 Momordica cochinchinensis Species 0.000 description 2
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001165 anti-coccidial effect Effects 0.000 description 2
- 230000003509 anti-fertility effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003640 drug residue Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- RNYZJZKPGHQTJR-UHFFFAOYSA-N protoanemonin Chemical compound C=C1OC(=O)C=C1 RNYZJZKPGHQTJR-UHFFFAOYSA-N 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- YSCJAYPKBYRXEZ-HZPINHDXSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YSCJAYPKBYRXEZ-HZPINHDXSA-N 0.000 description 1
- YDZWHGJRWMQCDP-NKILCQAGSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2s,3r,4 Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YDZWHGJRWMQCDP-NKILCQAGSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000027312 Bursal disease Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000172774 Ranunculus ternatus Species 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000192023 Sarcina Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002587 anti-hemolytic effect Effects 0.000 description 1
- 230000002158 anti-implantation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 150000002061 ecdysteroids Chemical group 0.000 description 1
- 230000000212 effect on lymphocytes Effects 0.000 description 1
- 230000000214 effect on organisms Effects 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- IEDOGKKOPNRRKW-UHFFFAOYSA-N octadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC IEDOGKKOPNRRKW-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- NCTHNHPAQAVBEB-WGCWOXMQSA-M sodium ferulate Chemical compound [Na+].COC1=CC(\C=C\C([O-])=O)=CC=C1O NCTHNHPAQAVBEB-WGCWOXMQSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Sustainable Development (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于防治鸡禽流感的复方黄芪多糖颗粒,可有效解决禽流感用药的问题,其解决的技术方案是,是由以下重量计的:黄芪20~30份,金银花10~20份,板蓝根15~35份,牛膝10~20份,当归10~20份,连翘10~30份,猫爪草20~30份和木鳖子仁5~15份作原料药物,经现代工艺提取浓缩后,再添加辅料制备成颗粒,所述的辅料为淀粉、糖粉、糊精的一种或两种以上的混合,本发明原料丰富,价格低廉,用药安全,对家禽类无任何刺激、毒副作用,对家禽类禽流感有很好的预防和治疗作用,而且可以提高机体免疫力,使用效果好,是防治禽流感的中兽药物上的创新。同时本发明的制作方法简单、成本低廉、使用方便,对家禽类禽流感的预防效果很好,适合大规模推广使用。
Description
技术领域
本发明属于制药技术领域,具体涉及一种防治鸡禽流感的复方黄芪多糖颗粒组合药物及其制备方法。
背景技术
禽流感是禽流行性感冒的简称,鸡禽流感的发病特点:①临床症状复杂,在临床上常与传支、传喉、大肠杆菌病等混合感染;②发病率和死亡率与毒株,鸡群性别,环境及并发症,继发感染有关,如禽流感病毒侵入黏膜,有利于大肠杆菌病继发,使禽流感病毒血凝素作用加强,导致鸡群发病率和死亡率增高;③禽流感病毒血清型很多,各型间交叉保护弱,同一血清型不同毒株的毒力差异很大;④禽流感病毒变异频率高,容易发生致病性变异及抗原漂移和转变,当前鸡禽流感危害及防治现状:①禽流感被发现100多年来,人类并没有掌握特异性的预防和治疗方法,仅能以消毒、隔离、大量宰杀禽畜的方法防止其蔓延,由此给养鸡业造成了极大地危害。②由于禽类感染禽流感后首先破坏机体的免疫防御***,导致机体的抵抗力和自身修复能力丧失;③西药抗病毒药用于临床后对病毒颗粒有部分拮抗作用,但是对于禽类的机体细胞也同样有毒副作用,兽医临床上西药抗病毒药物用于对禽类的禽流感防治效果并不理想。④在禽类的饲养过程中使用西药抗病毒药物后会导致食品安全等严重问题,从而影响到了人类的身体健康和人类疾病的防控安全,我国明确不允许使用西药抗病毒药用于畜禽禽流感的防治的,所以,目前在防治禽类的禽流感方面尚无抗病毒兽药。⑤在人类对于禽类的禽流感的临床防治研究与探索中发现部分中兽药品种如黄芪、金银花、板蓝根、木鳖子等用于防治禽类的禽流感的临床效果尚且不错,而且研究还发现黄芪等中兽药不但具有较强的临床抗病毒能力,同时还具有增强机体免疫力和抗病力,提高机体自身的修复能力。传统的中兽药由于加工工艺比较简单,相对加工粗糙,多以简单的粗粉或细粉或传统熬制后直接拌入禽类饲料或饮水中,中兽药的有效成分得不到充分有效的吸收利用,导致临床应用效果不太理想。因此,防治禽流感的药物上的改进是目前亟需解决的问题。
发明内容
针对上述情况,为解决现有技术之缺陷,本发明之目的就是提供一种防治鸡禽流感的复方黄芪多糖颗粒,可有效解决鸡禽流感防治用药的问题。
本发明解决的技术方案是:
是由以下重量计的:黄芪20~30份,金银花10~20份,板蓝根15~35份,牛膝10~20份,当归10~20份,连翘10~30份,猫爪草20~30份和木鳖子仁5~15份作原料药物,由以下步骤制得:
(1)所述的黄芪、金银花、板蓝根、当归、连翘、猫爪草分别除杂、晾干,按组方分别称取标准重量,分别粉碎成粒度为40~60目粗粉混合物备用;
(2)所述牛膝称取标准重量,经粉碎成粒度为40~60目粗粉备用;
(3)所述木鳖子去壳后,使用木鳖子仁除杂并称取标准重量备用;
(4)将所述步骤(1)的黄芪、金银花、板蓝根、当归、连翘、猫爪草混合物,加水浸提三次,第一次浸提用12倍金银花重量的水浸泡30~40min,文火煎煮1.5h,过滤,得第一滤液;第一次过滤药渣加入10倍混合物重量的水进行第二次浸提,文火煎煮1.5h,过滤,得第二滤液;第二次过滤药渣再加10倍混合物重量的水进行第三次浸提,文火煎煮1h,过滤,得第三滤液,合并第一滤液、第二滤液和第三滤液,浓缩至1:1的浓缩液,用浓缩液4倍体积量的无水乙醇沉淀,沉淀物干燥,得黄芪多糖等混合物;
(5)将所述步骤(2)的牛膝粗粉料加水,料液比1:15,100℃浸提2h,浸提液加牛膝5倍重量的质量浓度95%的乙醇,浸提2次,每次2h,合并滤液,浓缩,干燥,得牛膝多糖;
(6)将所述步骤(3)的木鳖子仁装入挤压式制霜机压制,控制温度为100℃,待出油量达17~20%时,停止压榨,将药渣粉碎混合均匀,得木鳖子霜;
(7)将以上所述步骤(4)步骤(5)步骤(6)分别制得的提取物进行充分混合后得提取混合物;
(8)按照颗粒剂制作工艺进行制浆,并将以上所述步骤(7)所得提取混合物再添加辅料,装入一步低温沸腾制粒机制备成颗粒,即得成品。所述的辅料为淀粉、糖粉、糊精的一种或两种以上的混合。
具体实施方式:
以下结合实施例对本发明的具体实施方式作进一步详细说明。
实例1:
本发明在具体实施时,是由以下重量计的:3、由权利1中所述本发明的复方黄芪多糖颗粒,其特征在于,是由以下重量计的:黄芪20份,金银花10份,板蓝根15份,牛膝10份,当归10份,连翘10份,猫爪草20份和木鳖子仁5份作原料药物,按照技术方案所述步骤制得成品。
实例2:
本发明在具体实施时,是由以下重量计的:黄芪30份,金银花20份,板蓝根35份,牛膝20份,当归20份,连翘30份,猫爪草30份和木鳖子仁15份作原料药物。按照技术方案所述步骤制得成品。
实例3:
本发明在具体实施时,是由以下重量计的:黄芪25份,金银花15份,板蓝根25份,牛膝15份,当归15份,连翘20份,猫爪草25份和木鳖子仁10份作原料药物。按照技术方案所述步骤制得成品。
上述本发明组方中各成分方解:
复方黄芪多糖颗粒的组方为:黄芪、金银花、板蓝根、牛膝、当归、连翘、猫爪草和木鳖子:
黄芪:近年来的研究发现黄芪中含多糖、皂甙、黄酮、氨基酸、微量元素等多种有效成分,这些活性成分均有促进抗体生成和免疫反应的作用,其中以对黄芪多糖(AstragalusPolysacharin,APS)的研究报道为多。黄芪多糖是黄芪的主要活性成分之一,经过高科技萃取、分离而得到的。黄芪多糖是黄芪发挥作用的主要成分,能促进机体代谢、抗疲劳、促进血清和肝脏蛋白质的更新,能增强和调节机体免疫功能,对干扰素***有促进作用可提高机体的抗病力,对流感病毒等多种病毒所致细胞病变有轻度抑制作用,对流感病毒感染小鼠有保护作用,还有有较广泛的抗菌作用;
金银花:清热解毒,疏散风热。用于痈肿疔疮,喉痹,丹毒,热毒血痢,风热感冒,温病发热。现代医学研究,金银花具有广泛的抗多种原微生物、抗炎和解、抗内毒素、兴奋中枢神经和加强免疫功能等作用;
板蓝根:清热解毒,凉血利咽。用于温毒发斑,舌绛紫暗,痄腮,喉痹,烂喉丹痧,大头瘟疫,丹毒,痈肿。研究表明,板蓝根(或:菘蓝的根茎)提取物通过限制病毒***而起到对甲型禽流感病毒,乙型禽流感病毒的抑制杀灭作用,其提取物的水溶液对普通感冒病毒有抑制作用,对流行性乙型脑膜炎病毒有抑制和杀灭作用,菘蓝根对多种细菌也有抑制作用,水浸液对枯草杆菌、金黄色葡萄球菌 、八联球菌、大肠杆菌、伤寒杆菌、副伤寒杆菌、痢疾(志贺、弗氏)杆菌、肠炎杆菌等都有不同程度的抑制作用;
牛膝:活血通经、补肝肾、强筋骨、利水通淋、引火(血)下行。现代研究:具有抗炎、镇痛等作用,能提高机体免疫功能。牛膝含有三萜皂苷(经水解后成为齐墩果酸和糖)、蜕皮甾酮、牛膝甾酮、紫茎牛膝甾酮等甾体类成分和多糖类成分。牛膝总皂苷对子宫平滑肌有明显的兴奋作用,怀牛膝苯提取物有明显的抗生育、抗着床及抗早孕的作用,抗生育的有效成分为蜕皮甾醇;
当归:补血活血,调经止痛,润肠通便。现代研究:当归还具有扶正抗癌、提升免疫、改善循环、抗炎镇痛、补血养肺、保肝利胆、护肾解毒、暖宫增蛋等功效。当归及其萃取物阿魏酸钠和当归多醣对单核-巨噬细胞***有明显的刺激作用,对免疫功能低下的机体也有免疫调解和恢复作用。当归对健康机体的淋巴细胞转化也有促进作用;
连翘:清热解毒,消肿散结。用于痈疽,瘰疠,乳痈,丹毒,风热感冒,温病初起,温热入营,高热烦渴,神昏发斑,热淋尿闭;现代研究:连翘具有解热和抗炎、抗菌、抗病毒、解毒(其抑菌成分为连翘酚、连翘脂苷A和挥发油。连翘脂苷B有抗真菌作用。其挥发油有显著抑制流感病毒的作用。还有抗内毒素的作用。)、保肝和镇吐、抗过敏等作用,临床用于治疗各种感染性疾病,包括病毒、细菌感染并发热,如普通感冒、上呼吸道感染、支气管炎、肺炎、胆囊炎、***,疮疖等,不论急性或慢性都宜使用。不论细菌、病毒、真菌都可使用。并有清除内毒素的作用。也可在使用抗生素的同时,与之同用能增效;
猫爪草:化痰散结,解毒消肿。现代研究:猫爪草含小毛茛内酯、原白头翁素、花生酸、肉豆蔻酸十八烷基酯、豆甾醇、β-谷甾醇、葡萄糖、***糖、半乳糖,还含油类及植物碱。具有较强的抗菌抗肿瘤、抗炎、改善体质和增强对疾病的抵抗力;
木鳖子:攻毒疗疮,消肿散结。现代研究:含木鳖子皂苷、木鳖子酸、木鳖子素、齐墩果酸、甾醇、氨基酸,以及油35.72%、蛋白质30.59%、海藻糖等。木鳖子皂苷有抗炎及降血压、抗溶血等作用。
实例4:复方黄芪多糖颗粒对鸡禽流感防治的临床试验研究
1材料和方法
1.1 试验材料
复方黄芪多糖颗粒;由河南纳瑞森生物药业有限公司按上述制备工艺和步骤制得,批号:2018041601;盐酸金刚烷胺:购自湖北某医药化工有限公司,批号:2018032002
1.2 试验鸡场选择与分组
试验安排在南阳市某禽业公司商品罗曼褐壳蛋鸡场处于45周龄不同发病阶段的三栋封闭式鸡舍,事先经采病料、血样经AGP、HI试验、细菌培养、病毒分离结合临床症状、病理剖检确诊为禽流感(AI)H9亚型。I栋10128只,完全随机分成试验组5064只,对照组5064只;II栋10243只完全随机分成试验组5120,对照组5123只;III栋10136只,完全随机分成试验组5068只,对照组5068只。三栋供试鸡均为45周龄罗曼褐商品代产蛋鸡。I栋鸡群为发病第3日龄,II栋鸡群尚未出现症状(已处于潜伏期),III栋鸡群为发病后第14日龄。
1.3 饲养管理
每栋均按正常的饲养管理办法进行饲养管理,各个饲养管理条件相同,各试验组与其相应的对照组管理办法亦完全一样。
1.4 试验方案
1.4.1各对照组用160mg/L的盐酸金刚烷胺饮水,试验组用复方黄芪多糖颗粒,试验I组剂量为200mg/L,试验II、III组剂量为 160mg/L,连续用药14d。
1.4.2每天观察并记录各组罗曼褐壳蛋鸡的精神、采食、饮水、粪便、发病数和死亡数等情况。
1.4.3本实验期间I栋、II栋、III栋鸡舍的实验组及对照组所产鸡蛋均严格做报废和无害化处理,使用盐酸金刚烷胺的三个对照组全部鸡只在试验结束后均严格跟踪监测,所产含有盐酸金刚烷胺药物残留的蛋品均严格做报废和无害化处理,待所实验的三个对照组蛋鸡机体血液、肝脏、肌肉及粪便均检测无盐酸金刚烷胺及其代谢残留物后视为该试验期全部结束。
1.5试验期间疫情变化
在本试验中II组罗曼褐壳蛋鸡群的对照组在试验的第4天两组开始发病,III组罗曼褐壳蛋鸡群的对照组在试验的第6天即初发后第20天复发禽流感H9亚型。
2 结果与分析
2.1复方黄芪多糖颗粒防治禽流感效果观察见表1:
表1:复方黄芪多糖颗粒防治禽流感效果观察试验结果
从试验结果可以看出,试验开始时各试验组与对照组产率水平相当(P>0.05),试验期中,各试验组在所有指标上明显优于相应的对照组,各试验组与相应的对照组比较,在发病率上I栋舍的试验组与对照组表现极显著性差异(P<0.01),II栋舍试验组与对照组表现基本相同(P>0.05),III栋舍的试验组与对照组表现显著性差异(P<0.05);在死亡率上I栋舍的试验组与对照组表现差异极显著(P<0.01),II栋舍、III栋舍两栋舍的试验组与对照组表现差异不显著(P>0.05);在产蛋率下降幅度上I栋舍、II栋舍、III栋舍三栋舍的试验组与对照组表现差异均极显著 (P<0.01),尤其是I栋舍的试验组与对照组的差异最显著,试验组产蛋率直接增长23.43%;在畸形蛋率上I栋舍、II栋舍、III栋舍三栋舍的试验组与对照组表现差异均显著 (P<0.05)。
2.2 复方黄芪多糖颗粒对蛋鸡禽流感免疫功能的影响
表2:复方黄芪多糖颗粒对蛋鸡禽流感免疫抗体水平和脾脏系数的影响
(同列数据肩标不同小写字母表示差异显著(P<0.05),不同大写字母表示差异极显著(P<0.01),相同字母或未标字母表示差异不显著(P>0.05)。)
由表2可见,在蛋鸡饲粮中添加不同水平的复方黄芪多糖颗粒,可以不同程度的提高蛋鸡禽流感血清免疫抗体水平,试验I、Ⅱ、Ⅲ、Ⅳ、Ⅴ组均显著高于对照组(P<0.05),但试验各组之间无显著差异(P>0.05)。在蛋鸡饲粮中添加不同水平的复方黄芪多糖颗粒,可以不同程度地提高脾脏系数,试验I、Ⅱ、Ⅲ、Ⅳ、Ⅴ组均显著高于对照组(P<0.05),但试验各组之间无显著差异(P>0.05)。
3 结论
通过本次防治试验及对蛋鸡禽流感免疫抗体水平和脾脏系数的影响检测的结果结合本病在当地的流行特点,可以得出下面几点结论:
3.1在禽流感发病的前、中、后三个阶段应用复方黄芪多糖颗粒添加防治,均可大大降低鸡的死亡率和产蛋率下降的幅度,复方黄芪多糖颗粒有明显的抗病毒、抗炎症作用;明显优于盐酸金刚烷胺。
3.2初次发病的耐过鸡群显然对本病能获得一定的免疫力,但因本病破坏鸡免疫***,不少鸡群往往在初发20~30d后会有不同程度地复发本病,如果初发后添加复方黄芪多糖颗粒可有效防止本病的复发。
3.3应用复方黄芪多糖颗粒防治本病在降低产蛋率下降、蛋壳质量恢复方面明显优于盐酸金刚烷胺。
3.4在蛋鸡饲粮中添加不同水平的复方黄芪多糖颗粒,显著提高蛋鸡禽流感抗体水平。从而有效的降低蛋鸡对禽流感的感染率和发病率,提高蛋鸡对禽流感的防御技能。
4、本发明复方黄芪多糖颗粒的功效和作用作用
4.1中医认为黄芪具有“补中益气,固表升阳,生肌,扶内固本”的药效。复方黄芪多糖颗粒是由中药黄芪通过精致提练而成,主要成分为黄芪多糖Ⅰ、黄芪多糖Ⅱ等多种免疫增强物质,再配以金银花、板蓝根、当归、连翘等提取物,牛膝多糖、猫爪草多糖和木鳖子霜等成分,互相支持,能激发机体产生大量白细胞干扰素和吞噬细胞、淋巴细胞,而且能强化体内的体液免疫途径,产生大量的免疫球蛋白和补体,改善微循环,有效地调理和增强机体的体液免疫和细胞免疫,提高机体免疫功能,对病毒产生干扰、吞噬、结合作用,多种途径杀灭病毒和细菌,并有清热解毒和调节机体代谢机能紊乱之功效,增强禽类抗病能力。
4.2复方黄芪多糖颗粒的功效:具有较强的清热解毒,扶正祛邪,培补脾肾,益气养血,广谱抗病毒、抗菌,能诱导机体产生干扰素,促进抗体形成,增强机体的免疫力和机体各***修复能力,抗病促长、抗应激等功能。尤其对禽类的禽流感防治效果最佳。
4.2.1广谱抗病毒的应用:复方黄芪多糖颗粒是一种广谱的抗病毒和干扰素诱导剂,它可刺激巨噬细胞和T细胞的功能,使E环形成细胞数增加,诱生细胞因子,促进白细胞介素诱生。从而使动物机体产生内源性干扰素,从而达到抗病毒的目的。用于治疗禽流感、传染性法氏囊病等病毒性传染病。复方黄芪多糖颗粒可预防感冒降低发病率80%以上,黄芪多糖与金银花、板蓝根、当归、连翘等提取物、牛膝多糖、猫爪草多糖、木鳖子霜联合应用可降低发病率90%以上。
4.2.2增强疫苗免疫力的应用:复方黄芪多糖颗粒除本身具有增强机体名疫力外,还使疫菌苗的免疫力大大增强,并且对疫菌苗具有很好的保护效果,据研究报道黄芪多糖能增强马立克氏病疫苗的血清拉体效价。复方黄芪多糖颗粒与NDV、IV疫苗联合使用能提高免疫后鸡的血清HI抗体效价,在使用球虫疫苗时配合复方黄芪多糖颗粒,能增强鸡球虫免疫保护力。
4.2.3对肝脏的作用:复方黄芪多糖颗粒可促进肝细胞DNA、RNA合成,减轻肝毒性物质引起的病变,增强肝脏解毒功能,对肝细胞有保护作用。对鸡脂肪肝、心包积水肝炎综合症、大肝脾病、肝炎脾肿大综合症均有良好的防治效果,同时可提高畜禽采食量,从而促使畜禽的生长发育。
4.2.4对肾脏作用:复方黄芪多糖颗粒可改善肾细胞代谢和肾功能,降低血肌酐水平,可缓解肾切除后肾功能衰竭。对肾病综合征、急性肾功能衰竭、肾病综合征、肾肿大尿酸盐沉积等症均有良好的防治效果。同时可起到健肾目的,有利于畜禽生长繁育功能的发挥。
4.2.5提高繁殖性能:复方黄芪多糖颗粒具有稳定细胞、抗衰老、抗自由基和过氧化的作用,长期定期使用,可明显提高种鸡的使用寿命和使用效率。此外,复方黄芪多糖颗粒具有促性腺作用,对雌性动物可以使子宫内膜增厚、子宫腔扩大、子宫角和卵巢的重量增加。复方黄芪多糖颗粒还可以提高雄性动物的繁殖性能,可使***活性、***存活率、***密度等有显著提高。
4.2.6是雏禽保健的第四需要:当前幼禽保健大多在三方面做文章:①预防病毒病的疫苗。②预防细菌病的抗生素。③增强体质、提高免疫力的营养物质。通过长期的实践研究发现,在满足雏禽以上三种保健需要的同时,实质上雏禽保健还存在有“第四需要”,那就是复方黄芪多糖颗粒。它不但可以充分发挥以上三种保健作用,还能满足雏禽保健无药物残留,充分发挥其生长潜力的需要。
4.2.7具有提高营养物质利用,促进动物生长的功能。复方黄芪多糖颗粒内含氨基酸、维生素、微量元素等多种营养物质,以及未知生长因子(UGF)。作为饲料添加剂可显著提高畜禽的生长速度,提升机体抵抗力,提高鸡蛋品质及产量。
5本发明的复方黄芪多糖颗粒的临床应用
5.1用于防治禽类的低致病性禽流感的临床预防和治疗及高致病性禽流感的有效免疫防控。
5.2有效治疗和预防家禽机体免疫功能低下(胸腺、肝脏、肾脏、法氏囊等器官萎缩);
5.3对肉禽生长速度缓慢、采食量低落、整齐度差,蛋禽无产蛋高峰或不明原因减蛋及顽固性水泻、脱肛等有特效。
5.4对疫苗有保护及协同作用,明显提升免疫效价,可以与疫苗同时使用。
5.5与抗球虫药物连用能明显提高抗球虫指数。
5.6防治畜禽各种病毒性疾病,如圆环病毒、蓝耳病、流行性感冒、伪狂犬、病毒性腹泻、反复发作性哮喘及无名高热等。
6 本发明结束语,本发明具有:
6.1复方黄芪多糖颗粒临床应用效果好,颗粒剂市场稀缺,比大众化的粉剂更有市场竞争力,科技含量高,附加值大。
6.2复方黄芪多糖颗粒采用超低温沸腾一步制粒颗粒制剂工艺,优势鲜明,便于保存和临床应用,更易切入市场。
6.3复方黄芪多糖颗粒性状稳定,水溶性极好,无毒,无害,无药残。
6.4原材料市场充足,工艺操作便捷,拌料、饮水方便均匀,产品开发前景广阔。
总之,本发明复方黄芪多糖颗粒经过多年研究、临床试验和对实践总结,确定本方组方可行有效,值得推广,有效用于鸡禽流感等病毒病的防治,复方黄芪多糖颗粒的研究成功与开发必将为社会创造出极大的经济效益和深远社会效益。
Claims (7)
1.一种用于防治鸡禽流感的复方黄芪多糖颗粒,其特征在于,是由以下重量计的:黄芪20~30份,金银花10~20份,板蓝根15~35份,牛膝10~20份,当归10~20份,连翘10~30份,猫爪草20~30份和木鳖子仁5~15份作原料药物。
2.由权利1中所述本发明的复方黄芪多糖颗粒,其特征在于,该颗粒剂由以下步骤制得:
(1)所述的黄芪、金银花、板蓝根、当归、连翘、猫爪草分别除杂、晾干,按组方分别称取标准重量,分别粉碎成粒度为40~60目粗粉混合物备用;
(2)所述牛膝称取标准重量,经粉碎成粒度为40~60目粗粉备用;
(3)所述木鳖子去壳后,使用木鳖子仁除杂并称取标准重量备用;
(4)将所述步骤(1)的黄芪、金银花、板蓝根、当归、连翘、猫爪草混合物,加水浸提三次,第一次浸提用12倍金银花重量的水浸泡30~40min,文火煎煮1.5h,过滤,得第一滤液;第一次过滤药渣加入10倍混合物重量的水进行第二次浸提,文火煎煮1.5h,过滤,得第二滤液;第二次过滤药渣再加10倍混合物重量的水进行第三次浸提,文火煎煮1h,过滤,得第三滤液,合并第一滤液、第二滤液和第三滤液,浓缩至1:1的浓缩液,用浓缩液4倍体积量的无水乙醇沉淀,沉淀物干燥,得黄芪多糖等混合物;
(5)将所述步骤(2)的牛膝粗粉料加水,料液比1:15,100℃浸提2h,浸提液加牛膝5倍重量的质量浓度95%的乙醇,浸提2次,每次2h,合并滤液,浓缩,干燥,得牛膝多糖;
(6)将所述步骤(3)的木鳖子仁装入挤压式制霜机压制,控制温度为100℃,待出油量达17~20%时,停止压榨,将药渣粉碎混合均匀,得木鳖子霜;
(7)将以上所述步骤(4)步骤(5)步骤(6)分别制得的提取物进行充分混合后得提取混合物;
(8)按照颗粒剂制作工艺进行制浆,并将以上所述步骤(7)所得提取混合物再添加辅料,装入一步低温沸腾制粒机制备成颗粒,即得成品,所述的辅料为淀粉、糖粉、糊精的一种或两种以上的混合。
3.由权利1中所述本发明的复方黄芪多糖颗粒,其特征在于,是由以下重量计的:黄芪20份,金银花10份,板蓝根15份,牛膝10份,当归10份,连翘10份,猫爪草20份和木鳖子仁5份作原料药物,按照权利2所述步骤制得成品。
4.由权利1中所述本发明的复方黄芪多糖颗粒,其特征在于,是由以下重量计的:黄芪30份,金银花20份,板蓝根35份,牛膝20份,当归20份,连翘30份,猫爪草30份和木鳖子仁15份作原料药物,按照权利2所述步骤制得成品。
5.由权利1中所述本发明的复方黄芪多糖颗粒,其特征在于,是由以下重量计的:黄芪25份,金银花15份,板蓝根25份,牛膝15份,当归15份,连翘20份,猫爪草25份和木鳖子仁10份作原料药物,按照权利2所述步骤制得成品。
6.根据以上权利要求1~5所述的应用,其中,所述应用包括所述成分及含量的中药组合物与清热解毒类中药、或在本成分配伍基础上的成分及含量参考性的加减同时施用。
7.根据权利要求6所述的应用,其中,所述制成的中兽药散剂、中兽药可溶性粉、中兽药口服溶液剂、中兽药丸剂等均在本专利保护之内。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111275085.0A CN113855729A (zh) | 2021-10-29 | 2021-10-29 | 一种用于防治鸡禽流感的复方黄芪多糖颗粒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111275085.0A CN113855729A (zh) | 2021-10-29 | 2021-10-29 | 一种用于防治鸡禽流感的复方黄芪多糖颗粒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113855729A true CN113855729A (zh) | 2021-12-31 |
Family
ID=78986262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111275085.0A Pending CN113855729A (zh) | 2021-10-29 | 2021-10-29 | 一种用于防治鸡禽流感的复方黄芪多糖颗粒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113855729A (zh) |
-
2021
- 2021-10-29 CN CN202111275085.0A patent/CN113855729A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078399B (zh) | 一种兽用抗病毒纯中药制剂 | |
CN105287790B (zh) | 一种鸡矢藤提取物及其应用 | |
WO2020155318A1 (zh) | 一种治疗家畜细菌性呼吸道疫病的中药制剂及其生产工艺 | |
CN101259160B (zh) | 治疗禽类病毒性疾病的复方制剂及其制备方法 | |
CN113855729A (zh) | 一种用于防治鸡禽流感的复方黄芪多糖颗粒 | |
CN104825700A (zh) | 一种抗菌消炎的中药组合物 | |
CN114886961A (zh) | 用于治疗/预防禽痛风的中药组合物及其制备方法、用途 | |
CN104721337A (zh) | 一种中药组合物及其制备方法和应用 | |
CN104825753B (zh) | 一种通过母猪服药防治新生仔猪腹泻的中药组合物 | |
CN109432287B (zh) | 一种防治家禽气分热盛证的中药口服液及其制备方法 | |
CN113559137A (zh) | 一种兽药颗粒剂的制粒方法 | |
CN111603514A (zh) | 一种兽用抗支原体感染的中药复方制剂及其制备方法和用途 | |
CN112089799A (zh) | 一种治疗鸡支气管栓塞的复方制剂及其制备方法 | |
CN101953987B (zh) | 一种提高鸡免疫力的中药组合物及其制备方法 | |
CN104758390A (zh) | 防治猪腹泻的植物药复方制剂及其制备方法 | |
CN113940966B (zh) | 一种治疗大肠杆菌感染的裸花紫珠组合物及其制备方法和应用 | |
CN111544570B (zh) | 一种添加抗菌肽的抗病毒制剂及其制备方法 | |
CN113750132A (zh) | 防治禽类禽流感的复方黄芪多糖可溶性粉 | |
CN104288260B (zh) | 一种有效防治猪呼吸道疾病的中兽药 | |
CN115531471B (zh) | 一种抗非洲猪瘟的组合物及其制备方法和应用 | |
CN103479786B (zh) | 一种用于治疗猪蓝耳病的中药组合物及其制备方法和应用 | |
CN103479860B (zh) | 一种用于治疗猪蓝耳病的中药组合物及其制备方法和应用 | |
CN112618692B (zh) | 一种防治仔猪黄白痢的中药组合物及其制备方法和用途 | |
CN103479789B (zh) | 一种用于治疗猪蓝耳病的中药组合物及其制备方法和应用 | |
CN109731044B (zh) | 一种治疗禽肠道感染的中药复方颗粒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |